In this pathway, JNK interacts with and binds to METTL3, which increases the m6A modification of mRNA, thereby elevating PD-1 levels and reducing the cytotoxic effectiveness of CD8+ T cells, leading to tumor immune evasion [302]. The gene discussed is CD8A; the disease is neoplasm.